It frames the shorter window as a deliberate consequence of USP standards that prioritize sterility and patient-specific preparation over extended stability
"Mazdutide (IBI362), a GLP-1/glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 2 trial." EClinicalMedicine 59 (2023)
Take 3 gummies before or after meals, especially higher-carbohydrate meals
Prioritize skin care
It also affects insulin sensitivity and cellular stress responses
and (4) the outcomes included the efficacy (liver enzyme levels, metabolic markers, hepatic fat content, and others) and/or safety [occurrence of nausea, constipation, diarrhea, and other adverse events (AEs)] of GLP-1RAs compared to the placebo or standard of care